Corvus Pharmaceuticals Reports $10.2 Million Net Loss, Sees Improvement in Financial Position

Corvus Pharmaceuticals, Inc. reported a net loss of $10.2 million for the three months ended September 30, 2025, a significant decrease from the $40.2 million loss recorded in the same period of the previous year. For the nine months ended September 30, 2025, the company posted a net loss of $3.0 million, compared to a loss of $50.2 million for the same period in 2024. The reduction in losses is attributed to a $27.1 million gain from the change in fair value of warrant liability, which contrasts with a $31.0 million loss in the prior year. Total operating expenses for the third quarter increased to $10.6 million from $7.3 million year-over-year, driven primarily by higher research and development costs associated with the ongoing clinical trials of its lead product candidate, soquelitinib.

The company’s financial position showed improvement, with total assets rising to $80.5 million as of September 30, 2025, up from $68.9 million at the end of 2024. Cash and cash equivalents decreased to $2.9 million from $8.7 million, while marketable securities increased to $62.8 million from $43.2 million. Corvus's accumulated deficit reached $400 million, reflecting the ongoing investment in research and development without any revenue generation from product sales, as none of its product candidates have yet received regulatory approval.

Operationally, Corvus is advancing its clinical programs, particularly for soquelitinib, which is currently in a Phase 3 trial for relapsed/refractory peripheral T cell lymphoma (PTCL) and a Phase 1 trial for atopic dermatitis. The company has also seen an increase in research and development expenses, which rose to $8.5 million in Q3 2025 from $5.2 million in Q3 2024, primarily due to increased drug manufacturing and clinical trial costs. The total employee headcount has also increased as the company expands its capabilities to support these clinical trials.

Looking ahead, Corvus Pharmaceuticals anticipates needing additional funding to support its operations, as its current cash and marketable securities are projected to be insufficient to cover planned expenditures beyond the fourth quarter of 2026. The company plans to raise capital through public and private equity offerings, debt financing, and potential collaborations. However, management has expressed substantial doubt about the company's ability to continue as a going concern for at least the next 12 months, emphasizing the need for timely capital to sustain its operations and development programs.